High serum interleukin-18 concentrations in patients with coronary artery disease and type 2 diabetes mellitus

European Cytokine Network

Volumn 16, Issue 3, 2005, Pages 177-185

  Suchanek, Hanna ^a   Myśliwska, Jolanta ^a   Siebert, Janusz ^a   Wiȩckiewicz, Joanna ^a   Hak, Łukasz ^a   Szyndler, Krzysztof ^a   Kartanowicz, Dorota ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Coronary artery disease; Interleukin 18; Type 2 diabetes mellitus

Indexed keywords

INTERLEUKIN 18; BIOLOGICAL MARKER;

ADULT; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARAMETER; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; DIABETIC ANGIOPATHY; MIDDLE AGED;

ANGINA;

BIOLOGICAL MARKERS; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; INTERLEUKIN-18; MALE; MIDDLE AGED;

EID: 33644680596     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281: 1291.
2. Unal B, Critchley JA, Capawell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981-2000. Circulation 2004; 109: 1101.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434.
4. Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, Davis BR, Holmes DR. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era. Circulation 2004; 109: 476.
5. McAlister FA, Man J, Bistritz L, Amad H, Tandon P. Diabetes and coronary artery bypass surgery: an examination of perioperative glycaemic control and outcomes. Diabetes Care 2003; 26: 1518.
6. Barsness GW, Peterson ED, Ohman EM, Nelson C, DeLong ER, Reves JG, Smith PK, Anderson D, Jones RH, Mark DB, Califf RM. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation 1997; 96:2551.
7. Luc G, Bard JM, Juhan-Vaque I, Ferrieres J, Evans A, Amouyel P, Arveiler D, Fruchart JC, Ducimetrire P. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease The PRIME study. Arterioscler Thromb Vasc Biol 2003; 23: 1255.
8. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore R, Pepys MP. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199.
9. Luc G, Arveiler D, Evans A, Amouyel P, Ferreres J, Bard JM, Elkhalil L, Fruchart JC, Ducimetrire P. Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: The Prime Study. Arteriosclerosis 2003; 170: 169.
10. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AFH. Inflammatory cytokines and the risk to develop type 2 diabetes. Results of the Prospective Population-Based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52: 812.
11. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004; 53: 693.
12. Ridker PM. Clinical application of C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2003; 103: 363.
13. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327.
14. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499.
15. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002; 195: 245.
16. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, Humbert Y, Chvatchko Y, Tedgui A. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerosis lesion development and stability. Circ Res 2001; 98: E41.
17. Elhage R, Jawien J, Rudling M, Ljunggren HG, Takrda K, Akira S, Bayard F, Hansson GK. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res 2003; 59: 234.
18. Mallat Z, Corbaz A, Scoazec A, Besnard S, Lesèche G, Chvatcho Y, Tedgui A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001; 104: 1598.
19. De Nooijer R, Von der Thüsen JH, Verkleij CJN, Kuiper J, Jukema JB, van der Val EE, van Berkel T, Biessen EAL. Overexpression of IL-18 decreases intimal collagen content and promotes a vulnerable plaque phenotype in apolipoprotein-E-deficient mice. Arterioscler Thromb Vasc Biol 2004; 24: 2313.
20. Yamashita H, Shimada K, Seki E, Mokuno H, Daida H. Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol 2003; 91: 133.
21. Yamaoka-Tojo M, Tojo T, Masuda T, Machida, Y, Kitano Y, Kurosawa T, Izumi T. C-reactive protein-induced production of IL-18 in human endothelial cells: mechanism of orchestrating cytokine cascade in acute coronary syndrome. Heart Vessels 2003; 18: 183.
22. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106: 24.
23. Blankenberg S, Luc G, Ducimetrière P, Arveiler D, Ferrières J, Amouyel P, Evans A, Combien F, Tiret L. Interleukin-18 and the risk of coronary heart disease in European men. Circulation 2003; 108: 2453.
24. Esposito K, Nappo F, Giugliano F, Di Palo C, Ciotola M, Paolisso G. Cytokine milieu tends toward inflammation in type 2 diabetes. Diabetes Care 2003; 26: 1647.
25. Esposito K, Nappo F, Giugliano F, Di Palo C, Ciotola M, Barbieri M, Paolisso G, Giugliano D. Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus. Am J Clin Nutr 2003; 78: 1135.
26. Aso Y, Okumara K, Takebayashi K, Wakabayashi S, Inukai T. Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-median wall thickness in patients with type 2 diabetes. Diabetes Care 2003; 26: 2622.
27. World Medical Association Declaration of Helsinki. Cardiovasc Res 1997; 35: 2-4.
28. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183.
29. Braunwald E. Unstable angina: a classification. Circulation 1989; 80: 410.
30. Kouroedov A, Eto M, Joch H, Volpe M, Luscher TF, Cosentino F. Selective inhibition of protein kinase Cβ 2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 2004; 110: 91.
31. Esposito K, Nappo F, Marfella R, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokines concentrations are acutely increased by hyperglycemia in humans. Circulation 2002; 106: 2067.
32. Marfella R, Siniscalchi M, Esposito K, Sellitto A. Effects of stress hyperglycemia on acute myocardial infarction. Role of inflammatory immune process is functional cardiac outcome. Diabetes Care 26: 3129.
33. Moriwaki Y, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S, Okamura H, Koga M, Fukuchi M, Hada T. 2003; Elevated levels of interleukin-18 and tumor necrosis factor -α in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 2003; 52: 605.
34. Esposito K, Pontillo A, Ciotola M, Di Palo C, Grella E, Nicoletti G. Giugliano D. Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab 2002; 87: 3864.
35. Marfella R, Esposito K, Siniscalchi M, Cacciapuoti F. Effect of weight loss on cardiac synchronization and proinflammatory cytokines in premenopausal obese women. Diabetes Care 2004; 27: 47.
36. Calhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, Thomson MJ, Mackness MI, Charltun-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multi-centre randomised placebo-controlled trial. Lancet 2004; 364: 685.
37. Van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C. DALI-Study Group. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003; 166: 129.
38. Nawawi H, Osman N, Annuar R, Khalid BA, Yusoff K. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. Atherosclerosis 2003; 169: 283.
39. Nawaki H, Osman NS, Yusoff K, Khalid BA. Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia. Horm Metab Res 2003; 35: 479.
40. Bays HE, Stein EA, Shah AK, Maccubin DL, Mitchel YB, Mercuri M. Effects of simvastatin on C-Reactive Protein in mixed hyperlipidemic and hypertrigliceridemic patients. Am J Cardiol 2002; 90: 942.
41. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003; 108: 1560.
42. Albert MA, Danielsson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation /CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 91.
43. Wolfrum S, Jensen KS, Liao JK. Endothelium dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23: 729.
44. Montero MT, Hernández O, Suárez Y, Matilla J, Ferruelo AJ, Martinez-Botas J, Gómez-Coronado D, Lasunción MA. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 2000; 153: 303.
45. Takahashi HK, Mori S, Iwagaki H, Yoshino T, Tanaka N, Nishibori M. Simvastatin induces interleukin-18 production in human peripheral blood mononuclear cells. Clin Immunol 2005; (Jun:2; Epub ahead of print).
46. Takahashi HK, Mori S, Iwagaki H, Yoshino T, Tanaka N, Weitz-Schmidt G, Nishibori M. Differential effect of LFA703, pravastatin and fluvastain on production of ICAM-1 and CD40 in human monocytes. J Leukoc Biol 2005; 77: 400.
47. Montero M, Matilla J, Gomeż-Mampaso E, Lasuncion MA. Geranylgeraniol regulates negatively caspase-1 autoprocessing: implication in the Th 1 response against Mycobacterium tuberculosis. J Immunol 2004; 173: 4936.
48. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253.
49. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 20: 145.
50. Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hofmayer D, Mohanty P, Tripathy D, Garg R. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an anti-inflammatory action. J Clin Endocrinol Metab 2003; 88: 4496.
51. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedresen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 1004.
52. Dandona P, Karne R, Ghanin H, Hamouda W, Aljada A, Magsimo CS. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 2000; 101: 122.
53. Mohanty P, Aljada A, Ghanin H, Hofmayer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P. Evidence for a potent anti-inflammatory effect of rosiglitazone. J Clin Endokrinol Metab 2004; 89: 2728.
54. Barua RS, Ambrose JA, Srivastava S, DeVoe MC, Eales-Reynolds LJ. Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and up regulation of endothelial nitric oxide synthase. An in vitro demonstration in human coronary artery endothelial cells. Circulation 2003; 107: 2342.
55. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Statchkov M, Thaiss F, Stahl RAK, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Muntzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001; 88: E14.
56. Barua RS, Ambrose JA, Eales-Reynolds LJ, DeVoe MC, Zervas JG, Saha DC. Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelial-dependent vasodilatation. Circulation 2001; 104: 1905.
57. Eliasson M, Asplund K, Nasic S, Rodu B. Influence of smoking and snuff on the prevalence and incidence of type 2 diabetes amongst men: the northern Sweden MONICA study. J Intern Med 2004; 256: 101.
58. Sairench T, Iso H, Nishimura A, Hosada T, Irie F, Saito Y, Muraka A, Fukotomi H. Cigarette smoking and risk of type 2 diabetes mellitus among middle-aged and elderly Japanese men and women. J Epidemiol 2004; 160: 158.